Effects of Niacin , Statin , and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia

Nov 30, 2016 by in CARDIOLOGY Comments Off on Effects of Niacin , Statin , and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia

Recent trials demonstrated substantial improvement in lipid parameters with inhibition of proprotein convertase subtilisin-like/kexin type 9 (PCSK9). Although statins and fibrates have been reported to increase plasma PCSK9 levels, the…

read more

Incidence of Emergency Department Visits for ST-Elevation Myocardial Infarction in a Recent Six-Year Period in the United States

Nov 30, 2016 by in CARDIOLOGY Comments Off on Incidence of Emergency Department Visits for ST-Elevation Myocardial Infarction in a Recent Six-Year Period in the United States

The incidence and longitudinal trends of patients with ST-elevation myocardial infarction (STEMI) presenting to United States (US) emergency departments (EDs) are currently unknown. Efforts to use effective treatments for cardiovascular…

read more

Impact of Thrombus Burden on Outcomes After Standard Versus Mesh-Covered Stents in Acute Myocardial Infarction (from the MGuard for Acute ST Elevation Reperfusion Trial)

Nov 30, 2016 by in CARDIOLOGY Comments Off on Impact of Thrombus Burden on Outcomes After Standard Versus Mesh-Covered Stents in Acute Myocardial Infarction (from the MGuard for Acute ST Elevation Reperfusion Trial)

Large thrombus burden negatively affects the results of percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). We investigated the impact of thrombus burden in patients with STEMI…

read more

Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention

Nov 30, 2016 by in CARDIOLOGY Comments Off on Impact of Lipoprotein(a) as Residual Risk on Long-Term Outcomes in Patients After Percutaneous Coronary Intervention

Cardiovascular risk remains uncertain in patients with cardiovascular disease despite achieving target lipid levels. Serum levels of lipoprotein(a) [Lp(a)] can be risk factors for adverse events. The aim of this…

read more
Get Clinical Tree app for offline access